Contact
Please use this form to send email to PR contact of this press release:
Initial Data from Allarity’s Phase 2 Trial of IXEMPRA® Indicate Potential for Improved Clinical Benefit in DRP®-Selected Metastatic Breast Cancer Patients
TO: